Gumprecht, Jakub http://orcid.org/0000-0002-0575-9150
Lip, Gregory Y. H.
Sokal, Adam
Średniawa, Beata
Mitręga, Katarzyna
Stokwiszewski, Jakub
Wierucki, Łukasz
Rajca, Aleksandra
Rutkowski, Marcin
Zdrojewski, Tomasz
Grodzicki, Tomasz
Kaźmierczak, Jarosław
Opolski, Grzegorz
Kalarus, Zbigniew
Clinical trials referenced in this document:
Documents that mention this clinical trial
Relationship between diabetes mellitus and atrial fibrillation prevalence in the Polish population: a report from the Non-invasive Monitoring for Early Detection of Atrial Fibrillation (NOMED-AF) prospective cross-sectional observational study
https://doi.org/10.1186/s12933-021-01318-2
Impact of diabetes mellitus severity, treatment regimen and glycaemic control on atrial fibrillation prevalence in the Polish population aged ≥ 65
https://doi.org/10.1038/s41598-023-43939-5
Funding for this research was provided by:
Narodowe Centrum Badań i Rozwoju (STRATEGMED2/269343/18/NCBR/2016)
Article History
Received: 20 April 2021
Accepted: 8 June 2021
First Online: 24 June 2021
Declarations
:
: Signed, informed consent was obtained from each eligible participant of the trial in accordance with protocol regulations approved by the local review boards governing research involving human subjects and local bioethical committee (26/2015), and the Declaration of Helsinki. The trial was registered on clinicaltrials.gov (NCT03243474).
: Not applicable.
: Gregory Y. H. Lip – Consultant and speaker for BMS/Pfizer, Boehringer Ingelheim and Daiichi-Sankyo. No fees are received personally. Other authors declare no conflict of interests.